Vaxart, Inc. (VXRT) Analysis

Oral pill vaccine safe, well-tolerated with strong blockade antibody responses

$VXRT We Did It!!!!The Reverse Split FAILED! Against all odds, and the full weight of management’s campaign, we stood together, informed ourselves, organized, and fought back. And it worked. The 1-for-50 reverse stock split FAILED because retail refused to be erased. We rejected the playbook of dilution, control consolidation, and long-term value destruction. This was more than just a vote it was a message: Retail owns this company, and we won’t be bullied or looked down upon. No matter ...

If this doesn’t sell you on it, I do not know what will. Check summary below (long read): Topline Phase 1 Results Study design: An open-label, head-to-head Phase 1 trial conducted in 60 healthy volunteers. Participants received either Vaxart’s first-generation oral norovirus vaccine, a high dose of the second-generation version (targeting GI.1 & GII.4 strains), or a lower dose of the second generation (n = 20 per group) . Primary measure: Norovirus-blocking antibody titers (NBAA) on Day 0 v...